Literature DB >> 16052081

Inhibition of HIV strains by GB virus C in cell culture can be mediated by CD4 and CD8 T-lymphocyte derived soluble factors.

Susan Jung1, Olivia Knauer, Norbert Donhauser, Melanie Eichenmüller, Martin Helm, Bernhard Fleckenstein, Heide Reil.   

Abstract

OBJECTIVE: A number of studies concerning the pathogenesis of GB virus C (GBV-C) in HIV-infected people suggest a beneficial effect and improved survival for dually infected individuals. However there has remained controversy regarding the clinical relevance of these findings, as some studies have not confirmed these observations. To address the possibility of direct inhibitory mechanisms, we studied the impact of GBV-C on HIV-1 replication in vitro.
METHODS: Peripheral blood mononuclear cells (PBMC) were infected with sera from GBV-C positive individuals or transfected with GBV-C specific RNA and superinfected with HIV. Replication kinetics of HIV were studied by quantification of HIV-p24 release. Induction of soluble antiretroviral factors were monitored with an HIV infection assay and by quantification of chemokine secretion. Changes in chemokine receptor expression were analysed by flow cytometry.
RESULTS: We demonstrate that GBV-C infection of PBMC leads to significant replication inhibition of R5- and X4-HIV isolates representing eight HIV clades. The inhibitory effect is mediated by GBV-C infection and also by expression of GBV-C structural glycoproteins and/or of non-structural proteins NS2/NS3. Upon GBV-C infection CD4 and CD8 T lymphocytes produce soluble HIV-suppression factors. Induction of stromal cell-derived factor (SDF)-1 and subsequent internalization of CXCR4 was not observed.
CONCLUSIONS: CD4 and CD8 T lymphocytes are stimulated by GBV-C to secrete antiretroviral factors, inhibiting R5- and X4-HIV strains. As no induction of SDF-1 and no down-regulation of the respective receptor CXCR4 could be observed, it is likely that additional unidentified factors causing inhibition of X4-HIV strains are induced by GBV-C.

Entities:  

Mesh:

Year:  2005        PMID: 16052081     DOI: 10.1097/01.aids.0000180097.50393.df

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  25 in total

1.  Transmission of GB virus type C via transfusion in a cohort of HIV-infected patients.

Authors:  Farnaz Vahidnia; M Petersen; G Rutherford; M Busch; S Assmann; J T Stapleton; B Custer
Journal:  J Infect Dis       Date:  2012-03-20       Impact factor: 5.226

2.  Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.

Authors:  Jinhua Xiang; James H McLinden; Thomas M Kaufman; Emma L Mohr; Nirjal Bhattarai; Qing Chang; Jack T Stapleton
Journal:  Virology       Date:  2012-05-16       Impact factor: 3.616

Review 3.  Role of GB virus C in modulating HIV disease.

Authors:  Carolynne Schwarze-Zander; Jason T Blackard; Juergen K Rockstroh
Journal:  Expert Rev Anti Infect Ther       Date:  2012-05       Impact factor: 5.091

4.  GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection.

Authors:  B Boodram; R C Hershow; D Klinzman; J T Stapleton
Journal:  J Viral Hepat       Date:  2011-04       Impact factor: 3.728

5.  Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding.

Authors:  James H McLinden; Thomas M Kaufman; Jinhua Xiang; Qing Chang; Donna Klinzman; Alfred M Engel; Georg Hess; Urban Schmidt; Michael Houghton; Jack T Stapleton
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

6.  Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.

Authors:  Yvonne Koedel; Kristin Eissmann; Holger Wend; Bernhard Fleckenstein; Heide Reil
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

7.  Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells.

Authors:  Jinhua Xiang; James H McLinden; Robert A Rydze; Qing Chang; Thomas M Kaufman; Donna Klinzman; Jack T Stapleton
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

8.  Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents.

Authors:  Solveig Tenckhoff; Thorsten Kaiser; Fritz Bredeek; Sharyne Donfield; Erika Menius; Alice Lail; Joachim Mössner; Eric S Daar; Hans L Tillmann
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

Review 9.  GB virus type C interactions with HIV: the role of envelope glycoproteins.

Authors:  Emma L Mohr; Jack T Stapleton
Journal:  J Viral Hepat       Date:  2009-09-15       Impact factor: 3.728

10.  GB virus type C E2 protein inhibits human immunodeficiency virus type 1 assembly through interference with HIV-1 gag plasma membrane targeting.

Authors:  Christine L Timmons; Qiujia Shao; Chenliang Wang; Ling Liu; Huanliang Liu; Xinhong Dong; Bindong Liu
Journal:  J Infect Dis       Date:  2013-01-09       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.